People living with HIV face a complex medical landscape that extends far beyond the virus itself. While antiretroviral therapies have drastically improved life expectancy and viral suppression, these individuals unfortunately remain at heightened risk for a host of non-AIDS-related comorbidities. Cardiovascular disease, liver conditions, various cancers, and chronic inflammatory states contribute significantly to morbidity and mortality within this population. A critical question remains: what are the molecular underpinnings that link HIV infection with these diverse and insidious health issues? Answering this question has been the focus of a groundbreaking study published in Nature Medicine, which leverages a comprehensive multi-omics approach to unravel the genetic and molecular landscape of comorbidities in people living with HIV.
This research, led by Prof. Yang Li and colleagues at the Centre for Individualised Infection Medicine (CiiM), a joint initiative of the Helmholtz Centre for Infection Research (HZI) and Hannover Medical School, represents the first large-scale study using integrative multi-omics data to explore the molecular drivers of HIV-related comorbidities. Utilizing data from the 2000HIV Study cohort based in the Netherlands, the team analyzed biological samples from over 1,300 individuals living with HIV. This cohort’s extensive dataset includes genomic, proteomic, and metabolomic profiles, offering unprecedented resolution into the molecular complexities underlying disease processes in these patients.
At the heart of this study is the concept of chronic inflammation—a persistent, low-grade inflammatory state that many people with HIV experience despite effective viral suppression. Chronic inflammation not only accelerates cellular aging but also predisposes individuals to conditions such as atherosclerosis, fibrosis, and malignancies. By correlating multi-omics layers of data, the researchers sought to identify specific molecular players and pathways that are implicated in driving these inflammatory and disease states.
One of the key innovations of this study was the integration of immune response profiling alongside traditional molecular analyses. The strength and regulation of the immune response is a dynamic measure of immune system fitness and resilience to pathogens. “By incorporating parameters that quantify immune responsiveness, we were able to connect molecular abnormalities directly to functional immune outcomes,” explains co-first author Nienke van Unen. This enabled the identification of not only disease markers but potential predictors of how an individual’s immune system might react to infections or additional physiological challenges.
The team’s analytical approach revealed a spectrum of previously undetected molecular correlations with major comorbidities, such as cardiovascular disease, carotid artery plaque formation, and chronic obstructive pulmonary disease (COPD). These findings illuminate a complex network of gene expression changes, protein signaling aberrations, and metabolic disruptions that collectively promote disease progression. “Our data uncovered molecular patterns that had evaded prior detection due to the isolated study of single omics layers,” states lead author Javier Botey-Bataller. The depth of these insights is powered by cross-level molecular comparison, which provides a systemic picture of pathogenesis rather than fragmented snapshots.
Crucially, the researchers identified molecular indicators capable of predicting the intensity of immune activation. Excessive immune responses, in particular, have been implicated as the principal drivers of systemic inflammation linked to comorbidities in HIV-positive individuals. The elucidation of these predictive markers opens the possibility for tailored therapeutic interventions aimed at modulating immune hyperactivation before irreversible tissue damage occurs. Such stratified approaches could profoundly improve long-term outcomes by mitigating the chronic inflammatory milieu.
Among the novel discoveries was a specific genetic variant of the NLRP12 gene, which emerged as a potential key regulator of inflammatory processes. NLRP12 belongs to a family of genes known to modulate inflammasome activity—a critical component of innate immunity and inflammation control. Participants harboring this variant exhibited markedly elevated inflammation levels regardless of HIV status, suggesting a broader susceptibility to inflammatory diseases beyond HIV infection itself. This insight underscores the interplay between host genetics and inflammation, offering new avenues for risk stratification and precision medicine.
The multi-omics dataset assembled for this investigation is openly accessible to the scientific community, fostering collaborative research and enabling further exploration into the molecular etiology of HIV-associated comorbidities. The availability of this rich resource is a significant contribution, providing a foundational platform from which future studies can unravel additional mechanistic details or validate therapeutic targets.
Importantly, this study sets a precedent for utilizing integrative molecular profiling in infectious disease research. By coupling genomic, proteomic, metabolomic, and immunological data, researchers can transcend traditional siloed analyses and capture the multifactorial nature of disease processes. This holistic methodology aligns with the emerging paradigm of individualized medicine, wherein patient management and treatment strategies are informed by nuanced molecular signatures tailored to each individual’s biology.
The implications of these findings extend beyond HIV research, as chronic inflammation is a common denominator in many age-related diseases and infections. Understanding how genetic variants like NLRP12 influence inflammatory pathways may have relevance for broader populations suffering from inflammatory and autoimmune disorders. Furthermore, the principle of mapping molecular landscapes to decode disease networks is applicable to numerous complex diseases, from cancer to neurodegeneration.
From a clinical perspective, the insights gathered could translate into more effective monitoring strategies for people living with HIV. The identification of molecular markers associated with comorbid conditions raises the possibility of developing blood-based diagnostic tests or biomarker panels that predict disease risk or progression. Early detection and intervention remain critical in managing these patients’ health, particularly given the accelerated aging and increased comorbidity burden observed.
Looking ahead, the research team envisions leveraging this molecular map to guide experimental studies aimed at dissecting the functional roles of specific genes and proteins in driving comorbidities. Such mechanistic work will be vital for validating candidate therapeutic targets and designing novel interventions. With the global population of people living with HIV continuing to grow, particularly among aging cohorts, these advances hold promise for improving quality of life and reducing healthcare burdens.
In sum, the study published in Nature Medicine marks a pivotal advancement in understanding the biological intricacies underpinning HIV-related comorbidities. By harnessing the power of multi-omics data and integrating immune response metrics, the research opens new horizons for precision medicine approaches tailored to the unique molecular profiles of individuals living with HIV. This work exemplifies the transformative potential of big data in biomedical research, forging a path toward more personalized, effective interventions for chronic inflammatory diseases.
—
Subject of Research: Genetic and molecular mechanisms underlying comorbidities in people living with HIV
Article Title: Genetic and molecular landscape of comorbidities in people living with HIV
News Publication Date: 20-Aug-2025
Web References: http://dx.doi.org/10.1038/s41591-025-03887-1
Keywords: HIV, comorbidities, chronic inflammation, multi-omics, personalized medicine, immune response, NLRP12 gene, cardiovascular disease, COPD, proteomics, metabolomics, genomics
